Comparator: pioglitazone
Sponsors
Merck Sharp & Dohme LLC
Conditions
Diabetes Mellitus Type 2Diabetes Mellitus, Type 2HealthyObesityOverweightType 2 Diabetes MellitusType 2 Diabetes Mellitus (T2DM)
Phase 1
Sitagliptin and Pioglitazone Mechanism of Action Study in Type 2 Diabetes Mellitus (0431-061)
CompletedNCT00511108
Start: 2007-07-11End: 2009-02-24Updated: 2017-05-12
Effects of Pioglitazone on Insulin Sensitivity in Healthy Overweight and Obese Males (MK-0000-170)
CompletedNCT01115712
Start: 2010-05-31End: 2010-09-30Updated: 2015-10-02
Phase 2
Phase 3
Pioglitazone Add-on Study in Patients With Type 2 Diabetes Mellitus
CompletedNCT00086502
Start: 2004-06-30End: 2005-11-30Updated: 2016-02-05
An Investigational Drug Study in Patients With Type 2 Diabetes Mellitus (MK0431-023)
CompletedNCT00094757
Start: 2004-10-06End: 2006-04-28Updated: 2019-05-30
Sulfonylurea Add-on Study in Patients With Type 2 Diabetes Mellitus (0431-035)
CompletedNCT00106704
Start: 2005-03-31End: 2007-01-31Updated: 2015-07-01
MK0431 (Sitagliptin) Pioglitazone Add-on Study for Patients With Type 2 Diabetes Mellitus (0431-055)(COMPLETED)
CompletedNCT00372060
Start: 2006-08-21End: 2008-02-05Updated: 2017-05-12
MK0431A vs. Pioglitazone in Patients With Type 2 Diabetes Mellitus (0431A-066)
CompletedNCT00532935
Start: 2008-01-26End: 2009-10-23Updated: 2017-06-09
A Study to Evaluate the Efficacy and Safety of Sitagliptin and MK0431A in Comparison to a Commonly Used Medication in Patients With Type 2 Diabetes (0431-068)(COMPLETED)
CompletedNCT00541450
Start: 2008-01-15End: 2010-01-16Updated: 2017-05-12
A Study to Evaluate the Safety and Efficacy of Sitagliptin 100 mg in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control (MK-0431-229)
CompletedNCT01076075
Start: 2010-06-03End: 2012-01-19Updated: 2017-06-05